A Study Exploring the Effect of Adjuvanted RZV or RSVPreF3 Vaccines on Coronary Plaque Progression in Adults >=50 Years of Age at Risk for Cardiovascular Events

NCT07712380 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

450

Enrollment

INDUSTRY

Sponsor class

Conditions

Cardiovascular Disease

Interventions

COMBINATION_PRODUCT: Placebo
COMBINATION_PRODUCT: Adjuvanted RZV vaccine
BIOLOGICAL: Adjuvanted RSVPreF3 vaccine

Sponsor

GlaxoSmithKline